Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Researchers at Tel Aviv University have achieved a breakthrough in drug delivery: they have successfully transported lipid ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

BOISE — Sen. Brandon Shippy, R-New Plymouth, is proposing to put a 10-year pause on certain types of vaccines that were used ...

New research reveals that sunburn may be caused by RNA damage, not DNA, challenging long-held beliefs about UV exposure ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Using a single-cell sequencing technique, Brazilian researchers have created the first cell atlas of focal cortical dysplasia ...

Discover how mRNA-based blood clots offer a promising new treatment for osteoarthritis, potentially surpassing traditional ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...